Completed PHASE4 INTERVENTIONAL 1-arm NCT00373360

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction

Sponsor: United Therapeutics

Conditions Pulmonary Hypertension

Interventions treprostinil sodium

Updated 8 times since 2017 Last updated: Jan 3, 2013 Started: Sep 30, 2006 Primary completion: Jan 31, 2008 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pulmonary Hypertension, this trial is completed. The trial is conducted by United Therapeutics and has accumulated 8 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

United Therapeutics

Data source: United Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States